For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

Convenient oral dosing

Tafinlar 150 mg twice daily + Mekinist 2 mg once daily1,2

Recommended starting dose: Tafinlar 150 mg twice daily + Mekinist 2 mg once daily.

 

References: 1. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 2. Mekinist Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017.